Bile acids (BAs) are a group of amphiphilic molecules consisting of a rigid steroid core
attached to a hydroxyl group with a varying number, position, and orientation, and a …

Nonalcoholic fatty liver disease (NAFLD) is primarily caused by abnormal lipid metabolism
and the accumulation of triglycerides in the liver. NAFLD is also associated with hepatic …

In this work, two series of benzoyl thiourea derivatives (TH01-TH05),(TH06-TH10) and their
metal complexes were successfully synthesized in good yields (up to 90%) using efficient …

Activation of LXR activity by synthetic agonists has been the focus of many drug discovery
efforts with a focus on treatment of dyslipidemia and atherosclerosis. Many agonists have …

Farnesoid X receptor (FXR) was considered as a promising drug target in the treatment of
cholestasis, drug-induced liver injury, and non-alcoholic steatohepatitis (NASH). However …

Myo-inositol (MI) has known to exert anti-diabetic, anti-oxidative and anti-inflammatory
properties. The present study examined the effects of MI supplementation on the expression …

Abstract Angiopoietin-like 3 (ANGPTL3) acts as an inhibitor of lipoprotein lipase (LPL),
impeding the breakdown of triglyceride-rich lipoproteins (TGRLs) in circulation. Targeting …

Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) are the most
problematic metabolic diseases in the world. NAFLD encompasses a spectrum of severity …

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a major health concern with
no approved pharmacological therapies. Molecules developed to activate the bile acid …

Non-alcoholic fatty liver disease (NAFLD) is common chronic metabolic liver disorder which
is associated with fat accumulation in the liver. It causes a wide range of pathological effects …